Norgine submits MAA to EMA for eflornithine in high-risk neuroblastoma: Netherlands Wednesday, January 8, 2025, 17:00 Hrs [IST] Norgine, a uniquely positioned, specialty pharmaceu ...
No need to get anxious over HMPV virus infection, it is not dangerous like coronavirus: Experts: Our Bureau, Chennai Wednesday, January 8, 2025, 16:45 Hrs [IST] Although two cases ...
Medanta strengthens its Renal Care Institute, appoints leading urologist Dr Sanjay Gogoi as chairman: Our Bureau, Mumbai Wednesday, January 8, 2025, 16:15 Hrs [IST] Reinforcing it ...
US FDA issues draft guidance on including tissue biopsies in clinical trials: Maryland Wednesday, January 8, 2025, 16:00 Hrs [IST] The US Food and Drug Administration (FDA) issued ...
WuXi Biologics grants exclusive global rights of trispecific t-cell engager to Candid Therapeutics: Shanghai Wednesday, January 8, 2025, 15:00 Hrs [IST] WuXi Biologics, a leading ...
AIOCD seeks Ministry of Railways to withdraw plans to rope in online pharmacies for home delivery of medicines: Our Bureau, New Delhi Wednesday, January 8, 2025, 14:10 Hrs [IST] T ...
US FDA issues new draft guidance aimed to help improve performance of pulse oximeters across skin tones: Maryland Wednesday, January 8, 2025, 14:00 Hrs [IST] The US Food and Drug ...
Bayer seeks China NMPA marketing authorization for ARi darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, January 8, 2 ...
Botanic Healthcare raises Rs. 250 crore to drive global expansion and market leadership: Our Bureau, Bengaluru Wednesday, January 8, 2025, 11:50 Hrs [IST] Botanic Healthcare, Indi ...
Biocon Biologics completes one-year as an integrated global biosimilars enterprise: Our Bureau, Bengaluru Wednesday, January 8, 2025, 11:30 Hrs [IST] Biocon Biologics in its first ...
US FDA issues comprehensive draft guidance for developers of AI -enabled medical devices: Maryland Wednesday, January 8, 2025, 11:00 Hrs [IST] The US Food and Drug Administration ...
US FDA grants breakthrough therapy designation to GSK’s B7-H3-targeted ADC, GSK’227 to treat relapsed or refractory osteosarcoma: London, UK Wednesday, January 8, 2025, 10:00 ...